Skip to content

Scailyte Announces a Collaboration with Turnstone Biologics

Scailyte Announces Collaboration with Turnstone Biologics

Scailyte Announces Collaboration with Turnstone Biologics 

Scailyte Announces Collaboration with Turnstone Biologics to Identify Biomarker Signatures in Solid Tumors with TIL Therapy

BASEL, Switzerland – Scailyte AG, an ETH Zürich spin-off with a proprietary analytical sequencing, and data analysis platform to draw insights into complex disease patterns from single-cell data, today announced that it entered into a collaboration with Turnstone Biologics to discover signature biomarkers predictive of clinical responses to tumor-infiltrating lymphocyte (TIL) therapy by applying ScaiVision®, Scailyte’s best-in-class single-cell sequencing analytical platform.

Scailyte’s proprietary data analysis platform, ScaiVision®, is designed to provide unique clinical insights into a patient’s biology to further enable cell and gene therapy and immuno-oncology treatments. ScaiVision® incorporates multi-modal single-cell datasets with clinical and technical endpoints, including disease diagnosis, progression, severity, treatment response, and toxicity response to identify sensitive biomarker signatures and cell therapy performance. 

Turnstone is a clinical-stage biotechnology company developing next-generation medicines to treat solid tumors by pioneering a differentiated approach with TIL therapy. Turnstone’s Selected TIL approach is driven by the identification, selection, and expansion of the most potent subsets of patient specific tumor-reactive T-cells to improve and broaden the clinical efficacy of TILs, and to overcome the limitations of current TIL-based therapies to achieve positive outcomes in multiple cancer indications. 

Under the terms of the agreement, Scailyte and Turnstone will collaborate with the goal of associating highly sensitive molecular biomarker patterns in TILs with clinical responses to TIDAL-01, Turnstone’s lead selected TIL therapy candidate. TIDAL-01 is currently being evaluated in two Phase 1b clinical studies in multiple indications, including melanoma, breast cancer, and colorectal cancer. Turnstone will collect TIL samples during the manufacture of patient-specific tumor-reactive TILs, and clinical samples after treatment with TIDAL-01. Scailyte will generate detailed transcript, epitope, and single-cell TCR sequencing datasets from the samples. These samples will be processed using ScaiVision® for automated pattern recognition and interpretation of single-cell transcriptomics and proteomics data to identify clinically relevant biomarker signatures in solid tumors.

About Scailyte

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets. 

Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

About Turnstone Biologics

Turnstone Biologics, a clinical-stage biotechnology company, is developing new medicines to treat solid tumors by pioneering a differentiated approach with tumor-infiltrating lymphocyte (TIL) therapy, a clinically validated technology. Turnstone’s innovative TIL therapy, which is designed to extend the efficacy of TILs to multiple solid tumor indications by selecting and manufacturing the most potent tumor-reactive T-cells (Selected TILs) for tumor eradication, represents the foundational therapeutic modality driving the Company’s cancer immunotherapy pipeline. The Company’s lead Selected TIL therapy candidate, TIDAL-01, is currently being evaluated in two Phase 1b studies in patients with multiple solid tumor indications. Turnstone is also advancing additional strategies to further potentiate the clinical benefit of Selected TILs, including use in combination with the Company’s novel viral immunotherapy. 

For more information, please visit www.turnstonebio.com, and follow Turnstone on LinkedIn.

Recent News

Meet Scailyte at Immuno-Oncology 360° in New York, USA

Our very own Diana Stoycheva and Peter Nestorov will be representing Scailyte at the conference at b...

Read more

Recent News

Inside Scailyte – Episode 5: Meet Daniel Schoener

Join us as we introduce you to Daniel Schoener, Executive Business Advisor at Scailyte AG. Daniel's ...

Read more

Recent News

ScaiDigest Volume 7: Unveiling Insights into Autoimmune Diseases

We're thrilled to share the latest installment of our ScaiDigest series, authored by our very own Di...

Read more

Recent News

Inside Scailyte – Episode 4: Meet Peter Evans

In this special episode, we introduce you to Peter Evans, our Principal IT Engineer at Scailyte AG. ...

Read more

Recent News

Inside Scailyte – Episode 3: Meet Peter Nestorov

Join us as Peter Nestorov, the Founder and CEO of Scailyte shares the pivotal role of Scailyte in th...

Read more

Recent News

Festival of Genomics 2024

Scailyte will be a part of the upcoming Festival of Genomics, on January 24th and 25th, 2024, in Lon...

Read more

Recent News

Inside Scailyte - Episode 2: Filipa Teixeira

We're back with another exciting episode of "Inside Scailyte," where we delve into the incredible jo...

Read more

Recent News

Single-cell omics and Al-fueled discovery to help endometriosis patients

Scailyte's powerful single-cell AI platform, ScaiVision, has played a pivotal role in a groundbreaki...

Read more

Recent News

01 /04

Meet Scailyte at Immuno-Oncology 360° in New York, USA

Our very own Diana Stoycheva and Peter Nestorov will be representing Scailyte at the conference at b...

Read more

Inside Scailyte – Episode 5: Meet Daniel Schoener

Join us as we introduce you to Daniel Schoener, Executive Business Advisor at Scailyte AG. Daniel's ...

Read more

Recent News

02 /04

ScaiDigest Volume 7: Unveiling Insights into Autoimmune Diseases

We're thrilled to share the latest installment of our ScaiDigest series, authored by our very own Di...

Read more

Inside Scailyte – Episode 4: Meet Peter Evans

In this special episode, we introduce you to Peter Evans, our Principal IT Engineer at Scailyte AG. ...

Read more

Recent News

03 /04

Inside Scailyte – Episode 3: Meet Peter Nestorov

Join us as Peter Nestorov, the Founder and CEO of Scailyte shares the pivotal role of Scailyte in th...

Read more

Festival of Genomics 2024

Scailyte will be a part of the upcoming Festival of Genomics, on January 24th and 25th, 2024, in Lon...

Read more

Recent News

04 /04

Inside Scailyte - Episode 2: Filipa Teixeira

We're back with another exciting episode of "Inside Scailyte," where we delve into the incredible jo...

Read more

Single-cell omics and Al-fueled discovery to help endometriosis patients

Scailyte's powerful single-cell AI platform, ScaiVision, has played a pivotal role in a groundbreaki...

Read more

Recent News